Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Cong-Ying Xie"'
Autor:
Yi‐Long Wu, Shun Lu, Ying Cheng, Qing Zhou, Hai‐Yan Tu, Qing‐Hua Zhou, Lv‐Hua Wang, Li Zhang, Jian‐Ying Zhou, Cheng Huang, Ming Chen, Cheng‐Ping Hu, Shao‐Kun Chuai, Xiao‐Nan Wang, Xiao‐Qing Liu, Ji‐Wei Liu, Peng‐Hui Zhou, Wei‐Zhi Chen, Ling‐Hua Yan, Yun‐Peng Liu, An‐Wen Liu, Xu‐Chao Zhang, Hui Li, Rong‐Rong Chen, Dong‐Mei Lin, Cong‐Ying Xie, Zheng‐Fei Zhu, Hui‐Ying Liang, Yong Song, Xiao‐Rong Dong, Ming‐Fang Zhao, Gui‐Bin Qiao, Jiu‐Wei Cui, Zi‐Ming Li, Zhi‐Jie Wang, Xiao‐Yuan Chen, Nong Yang, Gen Lin, Pan‐Wen Tian, Yun Fan, Qi‐Bin Song, Yuan Chen, Jian‐Chun Duan, Jia‐Lei Wang, Bo Zhu, Bu‐Hai Wang, Jun Zhao, Qi‐Tao Yu, Li‐Feng Wang, Hai‐Bo Zhang, Jie Hu, Rui Ma, Tong‐Mei Zhang, Jie Lin, Qian Chu, Sheng‐Xiang Ren, Yu Yao, Lin Wu, Hui‐Juan Wang, Fang Wu, Wen‐Zhao Zhong, Yi Hu, Ke‐Neng Chen, Jian Zhao, Fan Yang, Qun Wang, Dong‐Sheng Yue, Jian‐Ya Zhou, Peng Shen, Jia‐Tao Zhang, Xiao‐Long Yan, Mei‐Juan Huang, Wei‐Neng Feng, Li Li, Chinese Association of Lung Cancer, Guangdong Association of Clinical Trials (GACT)/Chinese Thoracic Oncology Group (CTONG)
Publikováno v:
Medicine Advances, Vol 1, Iss 4, Pp 293-305 (2023)
Abstract The importance of uncommon/rare oncogenic drivers in non‐small cell lung cancer (NSCLC) was underscored during the 20th China Lung Cancer Summit. These drivers, while present in a significant proportion of NSCLC patients, remain a challeng
Externí odkaz:
https://doaj.org/article/6cf86ef452334af4a74e37fd66750545
Autor:
Long-Hua Guo, Ming-Feng Zhang, He-Long Zhang, Jian-Ying Zhou, Xiao-Hong Cai, Yu Long, Qi-Sen Guo, Nong Yang, Jun Zhao, Zhan-Hong Xie, Bo Jiang, Ying Zhu, Yun Fan, Cong-Ying Xie, Yi Hu, Yu Yao, Jun Jia, Xiao-Ling Li, Jiu-Wei Cui, Xi-Zhao Sui, Wen Lin, Ying Cheng, Hui-Juan Wang, Chang-Li Wang, Ming-Fang Zhao, Gui-Bin Qiao, Li-Jun Peng, Lin Yang, Gong-Yan Chen, Kai-Can Cai, Xin-Hua Xu, Liang-Ming Zhang, Guo-Sheng Feng, Jing-Min Zhou, Guo-Wu Wu, Xiao-Rong Dong, Li-Feng Wang, Hong-Mei Zhang, Ya-Jie Gao, Qiu-Ying Jiang, Shun-Dong Cang, Zhi-Xiong Yang, Xia Song, Xiao-Qing Liu, Bo Zhu, Feng-Xia Chen, Chun-Hong Hu, Xi Chen, Yi-Long Wu, Qing Zhou
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Objective: This study investigated survival in selected Chinese patients with advanced lung adenocarcinoma who received initial chemotherapy with pemetrexed. We also explored the relationship between genetic biomarkers and pemetrexed efficacy.Methods
Externí odkaz:
https://doaj.org/article/e253b4aab9e84a8cb00e7d82934a0dd5
Publikováno v:
Algae; Mar2024, Vol. 39 Issue 1, p17-30, 14p
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
Immune checkpoint inhibitors (ICIs) expanded the therapeutic options for several cancers. However, whether some special groups of patients including those with organ transplantation can receive ICIs remains unclear. In this report we presented an int
Autor:
Changli Wang, Qiu-Ying Jiang, Jianying Zhou, Bo Zhu, Wang Lifeng, Qisen Guo, Qing Zhou, Guosheng Feng, Ming-Feng Zhang, Yi Hu, Jing-Min Zhou, Kaican Cai, Yun Fan, Guo-Wu Wu, Xi Chen, Xia Song, Xizhao Sui, Xiao-Hong Cai, Lin Yang, Xiao-Ling Li, Yi-Long Wu, Jun Jia, Ya-Jie Gao, Huijuan Wang, Xiaoqing Liu, Cong-Ying Xie, Xiaorong Dong, Shundong Cang, Ying Zhu, Mingfang Zhao, Wen Lin, Li-Jun Peng, Zhanhong Xie, Gongyan Chen, Gui-Bin Qiao, Liang-Ming Zhang, Jun Zhao, Xin-Hua Xu, Feng-Xia Chen, Helong Zhang, Bo Jiang, Chunhong Hu, Zhixiong Yang, Long-Hua Guo, Yu Yao, Nong Yang, Jiuwei Cui, Hongmei Zhang, Ying Cheng, Yu Long
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology, Vol 10 (2020)
Objective: This study investigated survival in selected Chinese patients with advanced lung adenocarcinoma who received initial chemotherapy with pemetrexed. We also explored the relationship between genetic biomarkers and pemetrexed efficacy.Methods
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:e236
PURPOSE/OBJECTIVE(S) Clinical evidence demonstrated that combination of radiotherapy and immunotherapy may be more effective than either treatment alone. However, the efficacy of combined treatment was limited due to the low response rate of immune c
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 66:S40-S46
Purpose: To evaluate the feasibility, toxicity, and clinical efficacy of simultaneous modulated accelerated radiation therapy boost technique for nasopharyngeal carcinoma. Method and Materials: Seventy-five patients with nasopharyngeal carcinoma were
Publikováno v:
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 35(5)
We aimed to perform a meta-analysis to assess the impact of radiotherapy (RT) on both 3- and 5-year survival in patients with resectable gastric cancer. Relevant studies were identified by using PubMed, Embase and the Cochrane Controlled Trials Regis
Publikováno v:
Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine. 33(1)
To investigate the effects and mechanisms of Curcumol beta-cyclodextrin Compound (CbetaC) on the proliferation and apoptosis of esophageal carcinoma cell line TE-1.The CbetaC was prepared by saturated solution and confirmed by infrared absorption spe
Publikováno v:
Zhonghua yi xue za zhi. 92(23)
To evaluate the safety and efficacy of radiation plus erlotinib in patients with esophageal cancer older than 70 years.Radiotherapy was prescribed at a daily fraction of 2.0 Gy up to a total dose of 60 Gy over 6 weeks. Concurrent erlotinib was admini